Review
Copyright ©2013 Baishideng Publishing Group Co.
World J Transplant. Dec 24, 2013; 3(4): 68-77
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.68
Table 1 Summary of investigational and available agents
GenericBrandFDA indicationCompany
Alefacept12AmeviveTreatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapyAstellas
Alemtuzumab2CampathTreatment of B-CLLBerlex Laboratories
ASKP1240Not FDA approvedAstellas
AzathioprineImuranAdjunctive therapy in prevention of rejection of kidney transplants; management of active rheumatoid arthritisGeneric manufacturers
BasiliximabSimulectPrevention of acute rejection in kidney transplantationNovartis
BelataceptNulojixPrevention of acute rejection in renal transplant recipientsBristol-Myers-Squibb
BortezomibVelcadeTreatment of multiple myeloma; treatment of relapsed or refractory mantle cell lymphomaMillenium Pharmaceuticals
CyclosporineNeoralPrevention of acute rejection in renal transplant recipientsNovartis
EculizumabSolirisTreatment of PNH to reduce hemolysis and aHUSAlexion Pharmaceuticals
Efalizumab12RaptivaManagement of moderate to severe chronic plaque psoriasis in adultsGenentech
EverolimusAfinitor, ZortressTreatment of advanced renal cell cancer (Afinitor®); treatment of subependymal giant cell astrocytom associated with tuberous sclerosis (Afinitor®); treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (Afinitor®); prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal transplants (Zortress®)Novartis
Mycophenolate MofetilCellceptProphylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal cardiac, or hepatic transplantsGenentech
Mycophenolate SodiumMyforticProphylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal transplantationNovartis
Horse or Rabbit anti-thymocyte GlobulinAtgam or ThymoglobulinTreatment of corticosteroid resistant rejection in kidney transplantationPfizer/Sanofi
RituximabRituxanTreatment of CD20-positive non-Hodgkin’s lymphomas ; Treatment of moderately- to severely-active rheumatoid arthritis in adult patients with inadequate response to one or more TNF antagonists; Treatment of Wegener’s granulomatosis; Treatment of microscopic polyangiitisGenentech
SirolimusRapamunePrevention of acute rejection in renal transplant recipientsPfizer
Sotrastaurin, AEB-0711Not FDA approvedNovartis
TacrolimusPrografPrevention of acute rejection in renal transplant recipientsAstellas
Tacrolimus Prolonged ReleaseAstragraf XLPreventing organ rejection in kidney transplant recipients, as combination therapy with mycophenolate mofetil and corticosteroids, with or without tasiliximab inductionAstellas
Tolfacitinib1XeljanzTreatment of moderate to severe rheumatoid arthritisPfizer
VoclosporinNot FDA approvedIsotechnika Pharma